Juniper Pharma Services has teamed up with CrystecPharma on a major multi-partner project as part of the Advanced Manufacturing Supply Chain Initiative (AMSCI) to help create a new platform to accelerate drug development in the future.

Both companies will collaborate as part of this UK-based consortium of partners that includes two of the world’s biggest pharmaceutical companies. The program aims to develop and demonstrate the capability of supercritical fluid technology in manufacturing smarter, higher quality pharmaceutical products, while moving products more quickly from research to the marketplace.

In just three years, AMSCI is expecting the joint platform to create products from concept to manufacture.

CrystecPharma designs crystals and particles aimed at meeting targeted performance requirements of a medicine. Juniper Pharma Services will bring its expertise in characterization, formulation development and GMP production to the supercritical fluid manufacturing platform.

“Working with CrystecPharma in collaboration with the other AMSCI partners is very exciting, as this alliance will produce a real step change in the advanced manufacturing of next-generation medicines,” said Nikin Patel, president, Juniper Pharma Services.

As a result of the project, CrystecPharma will refocus its manufacturing capability from China to the UK, working with Juniper Pharma Services as its international contract development and manufacturing organization (CDMO) partner. The technology company aims to develop three new products through this program.

“Such a collaborative campaign has the potential to really demonstrate the global competitiveness of the UK in pharmaceutical technology development and manufacturing,” said Paul Thorning, chief executive officer, CrystecPharma. “It will benefit from the invaluable expertise of the team at Juniper, which will enable our novel technology to move into a GMP compliant environment. Working closely with Juniper in this way allows us to rapidly establish the manufacturing capabilities needed to see us through to clinical trials.”